Research Topics
Genomes and Genes
Species | Torsten HaferlachSummaryAffiliation: MLL Munich Leukemia Laboratory Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Quantitative comparison of microarray experiments with published leukemia related gene expression signaturesHans Ulrich Klein
Department of Medical Informatics and Biomathematics, University of Munster, Domagkstrasse 9, 48149 Munster, Germany
BMC Bioinformatics 10:422. 2009..Here, we present a robust approach for a systematic and quantitative comparison of published gene expression signatures with an exemplary query dataset...
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]Torsten Haferlach
MLL Münchner Leukämie Labor, Munchen, Germany
Med Klin (Munich) 101:908-14. 2006..An ongoing international study (MILE study) is testing the accuracy, sensibility and specificity of gene expression profiling in leukemia diagnostics. First results and future directions will be given in the article...
Gene expression profiling for the diagnosis of acute leukaemiaT Haferlach
MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, Munich 81377, Germany
Br J Cancer 96:535-40. 2007..This method may therefore guide therapeutic decisions and should be investigated in a diagnostic setting in parallel to established standard methods...
Insight into the molecular pathogenesis of myeloid malignanciesTorsten Haferlach
MLL Munich Leukemia Laboratory, Germany
Curr Opin Hematol 14:90-7. 2007..Due to the rapid expansion of known molecular markers, this paper aims to outline some of the recent progress to improve understanding of the pathogenesis in these myeloid malignancies...
Diagnostic pathways in acute leukemias: a proposal for a multimodal approachTorsten Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
Ann Hematol 86:311-27. 2007....
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study GroupTorsten Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
J Clin Oncol 28:2529-37. 2010..The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories of myeloid and lymphoid malignancies...
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic featuresT Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
Leukemia 23:934-43. 2009..In conclusion, AML with t(8;16) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features and is a specific subtype of AML...
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersTorsten Haferlach
MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377, Munich, Germany
Ann Hematol 87:1-10. 2008..A stringent diagnostic algorithm for characterization, choice of treatment, and monitoring of MRD will be proposed in this review...
Modern diagnostics in acute leukemiasTorsten Haferlach
Laboratory for Leukemia Diagnostics, Medical Department III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistreet 15, 81377 Munich, Germany
Crit Rev Oncol Hematol 56:223-34. 2005..The results serve as a mandatory prerequisite for individual treatment strategies and for the evaluation of treatment response using especially newly defined and highly specific MRD markers...
Detailed analysis of FLT3 expression levels in acute myeloid leukemiaFlorian Kuchenbauer
Department of Internal Medicine III, Ludwig-Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
Haematologica 90:1617-25. 2005..INTERPRETATION AND CONCLUSIONS: FLT3 expression levels are correlated with clinical data, genetic subgroups as well as prognosis. Furthermore, our data indicate that FLT3 expression and signaling are closely associated with FAB M5...
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parametersClaudia Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
Genes Chromosomes Cancer 49:851-9. 2010..The proposed scoring systems for OS and TTT based on a combination of genetic markers improve the separation of prognostic subgroups in CLL already early in the course of the disease...
Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotypeTorsten Haferlach
MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
Leuk Res 36:51-8. 2012..Mean WBC count was highest in NPM1-mut/FLT3-ITD-positive and lowest in NPM1-wildtype/FLT3-ITD-negative patients (p<0.0001); similar for BM blasts. Therefore, FLT3-ITD and NPM1mut might synergistically stimulate blast proliferation...
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AMLSusanne Schnittger
MLL Munich Leukemia Laboratory, Munich, Germany
Blood 114:2220-31. 2009..Similar results were obtained in patients undergoing second-line chemotherapy or allogeneic stem cell transplantation...
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroupsClaudia Schoch
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Haematologica 89:1082-90. 2004..The 1225 patients with de novo AML were separated according to age as follows: A1: 16 to 49 years (n=442), A2: 50 to 59 years (n=246), A3: 60-69 years (n=333), A4: 70 years and older (n=204)...
Correlation of protein expression and gene expression in acute leukemiaWolfgang Kern
Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, Munich, Germany
Cytometry B Clin Cytom 55:29-36. 2003..In the future, diagnostic procedures may include oligonucleotide microarray analysis (MA) to detect expression patterns of large numbers of specific genes...
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemiaFlorian Kuchenbauer
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
Br J Haematol 130:196-202. 2005..6%) and associated with a significant lower overall survival (P = 0.0339). In addition, cases with bcr3 showed a tendency for a worse event-free survival (P = 0.0795) compared with the bcr1 group...
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemiaWolfgang Kern
Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, 81366 Muenchen, Germany
Blood 104:3078-85. 2004..MFC-based quantification of MRD reveals important prognostic information in unselected patients with AML in addition to cytogenetics and should be further evaluated and used in clinical trials...
Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemiaClaudia Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
Genes Chromosomes Cancer 51:257-65. 2012..4%, 56.4%, 34.0%, 12.6%; mEFS: n.r., 18.1 months, 8.7 months, 2.5 months). The impact on outcome of this score was independent of NPM1mut/FLT3-ITD- status, MLL-PTD, and age...
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative GroupTorsten Haferlach
Ludwig Maximilians University, University Hospital Grosshadern, Dept of Internal Medicine III, Munchen, Germany
Haematologica 89:408-18. 2004..To refine cytogenetically based risk-stratification in acute myeloid leukemia (AML)...
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Torsten Haferlach
Department of Medicine III, Ludwig Maximilians University, Grosshadern, Munich, Germany
J Clin Oncol 21:256-65. 2003..We also assessed the clinical significance of the recently introduced World Health Organization (WHO) classification for AML, which proposed dysplasia as a new parameter for classification...
Molecular characterization of acute leukemias by use of microarray technologyAlexander Kohlmann
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany
Genes Chromosomes Cancer 37:396-405. 2003..These data support a possible future application of microarray technology for classification of the acute leukemias...
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic featuresClaudia Haferlach
Munich Leukemia Laboratory GmbH, Munich, Germany
Blood 114:3024-32. 2009....
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CMLSusanne Schnittger
MLL Munich Leukemia Laboratory GmbH, Munich, Germany
Genes Chromosomes Cancer 49:910-8. 2010..Therefore, some KD mutations (e.g., T315I) might be associated with higher genetic instability paving the way to additional cytogenetic and molecular genetic events...
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyVera Grossmann
MLL Munich Leukemia Laboratory, Munich, Germany
J Mol Diagn 13:129-36. 2011..In conclusion, next-generation amplicon sequencing enables the highly sensitive detection of molecular mutations and is a feasible assay for routine assessment of GC-rich content amplicons...
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AMLMartin Weisser
Medical Department III, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
Leuk Lymphoma 48:2145-51. 2007..Our data (1) confirm that inv(3)/t(3;3) AML has a poor prognosis (2) show that age and initial WBC are risk factors for prognosis; (3) suggest that this group may benefit from allogeneic stem cell transplantation...
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not othMiriam Miesner
MLL Munich Leukemia Laboratory, Munich, Germany
Blood 116:2742-51. 2010..Thus, MLD alone showed no independent clinical effect, whereas cytogenetics and MDS history were prognostically relevant...
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrowWolfgang Kern
Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Dept of Internal Medicine III, Muenchen, Germany
Haematologica 88:646-53. 2003..The present analysis aimed at improving the applicability of this approach to more patients with AML...
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic eventsClaudia Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
Genes Chromosomes Cancer 51:328-37. 2012..Our study confirms the variety of ETV6 rearrangements in AML, MDS, and MPNs often in association with other genetic events. Prognosis of ETV6 rearranged de novo AML seems to be intermediate, which should be independently confirmed...
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotypeVera Grossmann
MLL Munich Leukemia Laboratory, Munich, Germany
Blood 118:6153-63. 2011..Finally, BCOR mutations tended to be associated with an inferior outcome in a cohort of 422 CN-AML patients (25.6% vs 56.7% overall survival at 2 years; P = .032). Our results for the first time implicate BCOR in CN-AML pathogenesis...
Pattern robustness of diagnostic gene expression signatures in leukemiaAlexander Kohlmann
Laboratory for Leukemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Genes Chromosomes Cancer 42:299-307. 2005....
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profileClaudia Schoch
Laboratory for Leukemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Genes Chromosomes Cancer 43:227-38. 2005..These data may be the basis for developing targeted therapeutic strategies to increase the cure rate in patients with AML and a complex aberrant karyotype...
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemiasWolfgang Kern
MLL Munich Leukemia Laboratory, Munich, Germany
Cancer 107:2401-7. 2006....
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemiaWolfgang Kern
Laboratory for Leukemia Diagnostics, Dept of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, 81366 Muenchen, Germany
Haematologica 89:528-40. 2004..We improved the identification of this parameter by implementing multiparameter flow cytometry to quantify bone marrow cells carrying leukemia-associated immunophenotypes (LAIP)...
Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLLWolfgang Kern
MLL Munich Leukaemia Laboratory, Max Lebsche Platz 31, Munich, Germany
Br J Haematol 157:86-96. 2012..These data emphasize a close relationship between MBL and CLL regarding clinically relevant parameters and provide no evidence to strictly separate these entities by a distinct threshold of clonal B-cells...
Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological dataSusanne Schnittger
MLL Munich Leukemia Laboratory, Munich, Germany
Genes Chromosomes Cancer 51:910-24. 2012..In conclusion, FLT3-mutations are extremely heterogenous with mutation load being the most relevant parameter...
Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemiaUlrike Bacher
Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
Cancer 106:839-47. 2006..The detection of minimal residual disease (MRD) for predicting prognosis and for therapeutic planning still are under discussion...
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemiaFrank Dicker
Munich Leukemia Laboratory GmbH, Munich, Germany
Blood 110:1308-16. 2007..The results of the present study indicate that in the absence of FLT3 mutations, FLT3 overexpression might be a mechanism for FLT3 activation, which cooperates with RUNX1 mutations in leukemogenesis...
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemiaClaudia Haferlach
MLL, Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
Haematologica 96:829-36. 2011..Alterations of the short arm of chromosome 12 (12p) occur in various hematologic malignancies and ETV6 and CDKN1B, which are located on 12p, have been implicated as leukemogenic genes of interest...
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosisSusanne Schnittger
Munich Leukemia Laboratory, Max Lebsche Platz 31, Munich, Germany
Blood 117:2348-57. 2011..Multivariate analysis showed independent prognostic relevance for overall survival for RUNX1mut (P = .029), FLT3-ITD (P = .003), age (P < .001), and white blood cell count (P < .002)...
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemiaWolfgang Kern
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University, University Hospital Grosshadern, 81366 Muenchen, Germany
Hematol J 5:410-8. 2004..08 log (range, 1.22-4.01) and 2.28 log (range, 1.12-3.34) with and without CD45 gating. CD45 gating improves the sensitivity of MFC-based MRD monitoring in AML by 1 log...
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridizationMirjam Klaus
Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
Cancer Genet Cytogenet 155:47-56. 2004..In conclusion, t(8;21), +11, +13, and +14 are strongly associated with AML M0, M1, and M2. The FISH screening analyses identified abnormalities in an additional 3% in normal karyotypes...
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcriptsSusanne Schnittger
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
Blood 102:2746-55. 2003..By combining the transcription ratios at these 2 checkpoints, a new powerful prognostic score has been established...
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasmsLena Reindl
Munich Leukemia Laboratory, Munich Interdisciplinary Clinic for Stem Cell Transplantation, Max Lebsche Platz 31, Munich, Germany
Br J Haematol 151:25-36. 2010..80·1 months, P = 0·015). In conclusion, the del(14q) is a rare recurrent alteration in diverse mature B-cell neoplasms, shows variable size but distinct clustering of breakpoints, and is associated with short time to treatment...
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemiaClaudia Schoch
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Hematol J 3:259-63. 2002..The introduction of all trans retinoic acid (ATRA) into treatment protocols has improved the outcome of APL dramatically. Therefore, it is essential to establish the diagnosis of APL as quickly and as reliably as possible...
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann
MLL Munich Leukemia Laboratory, Munchen, Germany
J Clin Oncol 28:3858-65. 2010..Thus far, data on a comprehensive cytogenetic or molecular genetic characterization are limited...
A novel hierarchical prognostic model of AML solely based on molecular mutationsVera Grossmann
MLL Munich Leukemia Laboratory, Munich, Germany
Blood 120:2963-72. 2012..9%); and (5) very unfavorable: TP53 mutation (n = 80; OS at 3 years: 0%; P < .001). This comprehensive molecular characterization provides a more powerful model for prognostication than cytogenetics...
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patientsFrauke Bellos
MLL Munich Leukemia Laboratory, Munich, Germany
Cytometry B Clin Cytom 82:295-304. 2012..It is suggested to be expressed more weakly in patients with myelodysplastic syndromes (MDS). The analysis of MNDA therefore may improve diagnostic capabilities of multiparameter flow cytometry (MFC) in MDS...
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemiaVera Grossmann
MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
Haematologica 96:1874-7. 2011..043). In conclusion, RUNX1 mutations are an important novel biomarker for a comprehensive characterization of T-cell acute lymphoblastic leukemia with poor prognostic impact and have implications for use also in monitoring disease...
Implications of NRAS mutations in AML: a study of 2502 patientsUlrike Bacher
Munich Leukemia Laboratory, Department of Internal Medicine III, University Hospital Munich, Ludwig Maximilians University, Max Lebsche Platz 31, 81377 Munich, Germany
Blood 107:3847-53. 2006..However, there was a trend to better survival in most subgroups, especially when other molecular markers (FLT3-LM, MLL-PTD, and NPM) were taken into account...
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISHClaudia Schoch
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
Genes Chromosomes Cancer 35:20-9. 2002....
Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four casesMartin Weisser
Medical Department III, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
Cancer Genet Cytogenet 177:64-9. 2007..In conclusion, the combined MDS-EVI1/EVI1 gene may serve as an alternative MRD marker in AML, especially in samples where other specific markers are lacking...
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotypeSusanne Schnittger
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilian s University, Munich, Germany
Blood 106:3733-9. 2005..In conclusion, this study demonstrates that NPM1+/FLT3-LM- mutations are an independent predictor for a favorable outcome in AML with normal karyotype...
Global approach to the diagnosis of leukemia using gene expression profilingTorsten Haferlach
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich
Blood 106:1189-98. 2005..Accordingly, cluster analysis completely separated all 13 subgroups analyzed. Gene expression profiling can predict all clinically relevant subentities of leukemia with high accuracy...
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemiaHannes Herholz
MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
Cancer Genet Cytogenet 174:57-60. 2007..Deleted sites on 13q14 appeared to be located within the breakpoint regions of the translocations. We show that mechanisms other than interstitial deletions may lead to loss of critical chromosomal regions in CLL...
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findingsDaniela Voskova
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
Cytometry B Clin Cytom 62:25-38. 2004..In most patients with acute myeloid leukemia, multiparameter flow cytometry may be used to monitor minimal residual disease...
Role of gene expression profiling for diagnosing acute leukemiasWolfgang Kern
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
Rev Clin Exp Hematol 9:E1. 2005..Furthermore, it is anticipated that new biologically defined and clinically relevant subtypes of leukemia will be identified based on gene expression profiling. This method may therefore guide therapeutic decisions...
Gene expression profiling as a tool for the diagnosis of acute leukemiasTorsten Haferlach
Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
Semin Hematol 40:281-95. 2003..Gene expression profiling should also lead to the detection of new biological and clinically relevant subtypes in leukemia and therefore guide therapeutic decisions...
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemiaUlrike Bacher
Department for Internal Medicine III, Klinikum, Grosshadern, Ludwig Maximilians University, Munich, Germany
Haematologica 90:1502-10. 2005..However, detailed data on the population-based age-dependent incidences of distinct cytogenetic subtypes as well as of molecular mutations are lacking...
Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroupsClaudia Schoch
Munich Leukemia Laboratory MLL, Munich 81377, Germany
Genes Chromosomes Cancer 45:1164-8. 2006..Therefore, trisomy 8 in AML determines no specific disease characteristic but is a disease modulating secondary event...
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemiasSusanne Schnittger
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
Genes Chromosomes Cancer 45:332-7. 2006..001). In addition, 21 of 234 CML (9.0%) and 7 of 155 ALL (4.5%) cases carried the FLT3 D324N. Our data suggest that the FLT3 D324N variant might be associated with a predisposition to different subtypes of leukemia...
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophiliaUlrike Bacher
Department of Clinical Chemistry, Ludwig Maximilians University, Munich Marchioninistr 15, 81377 Munich
Haematologica 91:817-20. 2006..A FIP1L1-PDGFRA fusion gene was identified in four male patients by interphase FISH and RT-PCR. These methods in combination demonstrated clonality in 8/40 patients (20%) with a male predominance (6/8; 75%)...
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study GroGeorg Lenz
Department of Internal Medicine III, Ludwig Maximilians University, University Hospital Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
J Clin Oncol 22:4926-33. 2004....
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypesTorsten Haferlach
Laboratory for Leukemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Genes Chromosomes Cancer 43:113-27. 2005..0001), may partly contribute to the different phenotypes. However, linear regression analysis demonstrated that genes differentially expressed between M3 and M3v did not correlate with FLT3-LM...
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflowSusanne Schnittger
MLL Munich Leukemia Laboratory, Munich, Germany
Haematologica 97:1582-5. 2012..In cases in which a myeloproliferative neoplasm cannot be established, analysis for TET2, CBL and EZH2 mutations may be indicated...
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemiaSusanne Schnittger
MLL Munich Leukemia Laboratory, Munich, Germany
Blood 119:3151-4. 2012..001). In conclusion, we confirmed BRAFmut as a useful marker in HCL, its absence in HCL variant, and developed an RT-PCR-based assay to monitor minimal residual disease in HCL...
Discussion of the applicability of microarrays: profiling of leukemiasTorsten Haferlach
MLL Münchner Leukämielabor GmbH, Munchen, Germany
Methods Mol Biol 509:15-33. 2009..This could also lead to the identification of new targets for future drugs...
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 statusSusanne Schnittger
Munich Leukemia Laboratory, Munich, Germany
Blood 116:5486-96. 2010..039) especially in the age group < 60 years (P = .028). In conclusion, these data show that IDH1R132 may significantly add information regarding characterization and prognostication in AML...
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patientsUlrike Bacher
Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377, Munich, Germany
Ann Hematol 84:785-91. 2005..In conclusion, the central role of morphology as defined by the FAB and WHO classification in AML at diagnosis is still justified in combination with other techniques...
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survivalSusanne Schnittger
Laboratory of Leukemia Diagnostics and Clinical Cooperative Group Leukemia, Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Blood 107:1791-9. 2006..Patients with KIT-D816-positive/AML1-ETO-positive AML might benefit from early intensification of treatment or combination of conventional chemotherapy with KIT PTK inhibitors...
Monitoring of minimal residual disease in acute myeloid leukemiaWolfgang Kern
Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, 81366 Muenchen, Germany
Crit Rev Oncol Hematol 56:283-309. 2005..Thus, it is desirable to establish new molecular markers for PCR-based studies. Large clinical trials will determine the role and place of immunologic and PCR-based monitoring in the prognostic stratification of patients with AML...
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapyMartin Weisser
Laboratory for Leukemia Diagnostics, Medical Department III, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
Haematologica 90:881-9. 2005....
Gene expression profiling as a diagnostic tool in acute myeloid leukemiaWolfgang Kern
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
Am J Pharmacogenomics 4:225-37. 2004..Furthermore, gene expression profiling may also lead to the detection of new biologically defined and clinically relevant subtypes in leukemia and guide therapeutic decision-making in the future...
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML casesClaudia Schoch
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377 Munchen, Germany
Blood 102:2395-402. 2003..0 vs 8.9 months, P =.36). In conclusion, the category AML with 11q23/MLL abnormalities accounts for 2.8% of unselected AML, is closely associated with monocytic differentiation, and has a dismal prognosis. (..
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangementMirjam Klaus
Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, 81377 Munich, Germany
Cancer Genet Cytogenet 144:36-43. 2003..Compared to translocations involving MLL and other partner genes, complex rearrangements are unique for MLL-AF10 fusions. This may result from the opposite orientation of MLL and AF10...
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemiaKarsten Spiekermann
Clinical Cooperative Group Leukemia, GSF, National Research Center for Environment and Health, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
Blood 100:3423-5. 2002..Our results show for the first time that in addition to known mutations in the JM and the catalytic domain, further activating length mutations exist in the FLT3 gene...
Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disordersUlrike Bacher
Department for Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistr 15, D 81377 Munich, Germany
Cancer Genet Cytogenet 160:179-83. 2005..The prognostic impact of this unbalanced aberration and of gains of 9p in chronic myeloproliferative disorders remains to be clarified...
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]Torsten Haferlach
MLL Münchner Leukämielabor GmbH, Munchen
Med Klin (Munich) 102:770-7. 2007..Thus, diagnostics in the CMPD transform toward a multimodal diagnostic concept based on a combination of methods - cyto-/histomorphology, cytogenetics, and individual molecular methods which can be included in a diagnostic algorithm...
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 TrialWolfgang Kern
Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, Muenchen, Germany
Blood 101:64-70. 2003..0001), LDH (P <.0001), and day 16 blasts (P =.0359). The prognostic significance of day 16 blasts is independent of pretherapeutic parameters and predicts outcome even in patients achieving a CR...
Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical dataWolfgang Kern
MLL Munich Leukemia Laboratory, Munich, Germany
Cancer 116:4549-63. 2010..The diagnosis and classification of myelodysplastic syndromes (MDS) is based on cytomorphology (CM) and cytogenetics (CG). Multiparameter flow cytometry (MFC) may add important diagnostic information...
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expressionFrank Dicker
MLL Munich Leukemia Laboratory GmbH, Max Lebsche Platz 31, 81377 Munich, Germany
Blood 108:3152-60. 2006..We demonstrate that FISH analysis underestimates the complexity of chromosomal aberrations in CLL. Therefore, conventional cytogenetics may define subgroups of patients with high risk of progression...
RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemiaSusanne Schnittger
MLL Munich Leukaemia Laboratory GmbH, Munich, Germany
Br J Haematol 146:665-8. 2009..Thus, increasing WT1 levels in molecular responders may indicate Ph-negative clonal cytogenetic evolution during imatinib treatment...
Monitoring of minimal residual disease in acute myeloid leukemiaWolfgang Kern
MLL Munich Leukemia Laboratory, Munich, Germany
Cancer 112:4-16. 2008..Large clinical trials will determine the exact role and place of immunologic and RQ-PCR-based monitoring of MRD in the therapy of patients with AML...
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH studyAlexander Kohlmann
Munich Leukemia Laboratory, Munich, Germany
Clin Chem 54:1705-15. 2008..Gene expression profiling has the potential to offer consistent, objective diagnostic test results once a standardized protocol has been established. We investigated the robustness, precision, and reproducibility of microarray technology...
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profilesClaudia Schoch
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, 81366 Munich, Germany
Proc Natl Acad Sci U S A 99:10008-13. 2002..By using two different strategies for microarray data analyses, this study revealed a unique correlation between AML-specific cytogenetic aberrations and gene expression profiles...
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia veraSusanne Schnittger
MLL, Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
Haematologica 94:414-8. 2009..262; p=0.012). Median age of onset was lower than in the V617Fmut controls (58.5 vs. 67.8 years, p<0.001). In conclusion, JAK2 exon 12 mutation analysis contributes to diagnostics in polycythemia vera or erythrocytosis...
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemiaWolfgang Kern
MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, Munich 81377, Germany
Cytometry B Clin Cytom 76:385-93. 2009..ZAP-70 provides an important prognostic information in chronic lymphocytic leukemia (CLL); however, the most appropriate antibody clone and way of analysis have not yet been defined...
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid informationUlrike Bacher
Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
Ann Hematol 84:250-7. 2005..In ET and in HES the aberration rate was only 3 and 7%, respectively. Thus, cytogenetics can be omitted. However, in some of these cases molecular procedures should be integrated into the routine diagnostic process...
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patientsUlrike Bacher
Bone Marrow Transplant Unit, University Hospital of Hamburg Eppendorf, Hamburg, Germany
Blood 111:2527-37. 2008..In contrast, we found an additional favorable impact of FLT3-TKD on EFS in prognostically favorable AML with NPM1- or CEBPA mutations...
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17)Elise Chapiro
Department of Hematology, , , , , Paris, France
Blood 108:3484-93. 2006..They are also consistent with the existence and subsequent transformation of progenitor populations with lymphoid/myeloid potential...
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid lClaudia Schoch
Haematologica 88:351-2. 2003
Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligationAbdul A Peer Zada
Medicine III, University of Munich Hospital Grosshadern and GSF Hematologikum, Germany
Oncogene 22:2296-308. 2003..Moreover, targeting of G1 regulatory proteins and the resulting induction of G1 arrest by A3D8 may provide new insights into antiproliferative and differentiation therapy of AML...
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
Haematologica 93:439-42. 2008..Taken together, these findings make NPMc+ acute myeloid leukemia a good candidate for inclusion in the upcoming World Health Organization classification...
Prognosis in therapy-related acute myeloid leukemia and impact of karyotypeWolfgang Kern
J Clin Oncol 22:2510-1. 2004
[Molecular classification in leukemias using gene expression profiling]Torsten Haferlach
Labor für Leukämiediagnostik, Medizinische Klinik III Ludwig Maximilians Universität Klinikum Grosshadern, Munchen
Med Klin (Munich) 99:464-6. 2004..This new technique should be further validated in parallel to the standard work-flow and has to be proven before substituting other methods in the future...
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual diseaseSusanne Schnittger
Department of Internal Medicine III, University of Munich, Germany
Blood 100:59-66. 2002..6 months; P =.0072) because of a higher relapse rate. Besides the importance of FLT3-LM for biologic and clinical characterization of AML, we show its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients...
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotypeKai Neben
Division of Molecular Genetics B060, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
Oncogene 24:1580-8. 2005..In conclusion, we showed that unique gene expression patterns can be correlated with FLT3-ITD and FLT3-TKD. This might lead to the identification of further pathogenetic relevant candidate genes particularly in AML with normal karyotype...
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemiaMartin Weisser
Leuk Lymphoma 47:2645-7. 2006
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion geneChristoph Walz
, , Mannheim, Germany
Genes Chromosomes Cancer 45:950-6. 2006....
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemiaUlrike Bacher
Haematologica 90:558-9. 2005..The incidence of submicroscopic deletions was 2-9% depending on the entity...
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent eventsGerhard Herzog
Haematologica 90:693-5. 2005..We performed allelotyping and p53 mutation analysis in 75 patients with morphologically and cytogenetically classified AML...
Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETOTobias Berg
Department of Medicine, Division Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
Haematologica 93:1728-33. 2008..The increased expression of p21/WAF/Cip1 in primary leukemic blasts suggests that elevated p21/WAF/Cip1 levels may contribute to specific features observed in AML1-ETO positive leukemia...
